27 related articles for article (PubMed ID: 38652038)
1. Correction to: TBC1D5 reverses the capability of HIF‑2 in tumor progression and lipid metabolism in clear cell renal cell carcinoma by regulating the autophagy.
Huang Y; Xiong Z; Wang J; Gao Y; Cao Q; Wang D; Shi J; Chen Z; Yang X
J Transl Med; 2024 May; 22(1):505. PubMed ID: 38802839
[No Abstract] [Full Text] [Related]
2. HIF2 Inactivation and Tumor Suppression with a Tumor-Directed RNA-Silencing Drug in Mice and Humans.
Ma Y; Joyce A; Brandenburg O; Saatchi F; Stevens C; Toffessi Tcheuyap V; Christie A; Do QN; Fatunde O; Macchiaroli A; Wong SC; Woolford L; Yousuf Q; Miyata J; Carrillo D; Onabolu O; McKenzie T; Mishra A; Hardy T; He W; Li D; Ivanishev A; Zhang Q; Pedrosa I; Kapur P; Schluep T; Kanner SB; Hamilton J; Brugarolas J
Clin Cancer Res; 2022 Dec; 28(24):5405-5418. PubMed ID: 36190432
[TBL] [Abstract][Full Text] [Related]
3. Upstream stimulatory factor 2 and hypoxia-inducible factor 2α (HIF2α) cooperatively activate HIF2 target genes during hypoxia.
Pawlus MR; Wang L; Ware K; Hu CJ
Mol Cell Biol; 2012 Nov; 32(22):4595-610. PubMed ID: 22966206
[TBL] [Abstract][Full Text] [Related]
4. CD70-Targeted Micelles Enhance HIF2α siRNA Delivery and Inhibit Oncogenic Functions in Patient-Derived Clear Cell Renal Carcinoma Cells.
Trac N; Oh HS; Jones LI; Caliliw R; Ohtake S; Shuch B; Chung EJ
Molecules; 2022 Dec; 27(23):. PubMed ID: 36500549
[TBL] [Abstract][Full Text] [Related]
5. STAT3 or USF2 contributes to HIF target gene specificity.
Pawlus MR; Wang L; Murakami A; Dai G; Hu CJ
PLoS One; 2013; 8(8):e72358. PubMed ID: 23991099
[TBL] [Abstract][Full Text] [Related]
6. Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment.
Garcia Garcia CJ; Huang Y; Fuentes NR; Turner MC; Monberg ME; Lin D; Nguyen ND; Fujimoto TN; Zhao J; Lee JJ; Bernard V; Yu M; Delahoussaye AM; Jimenez Sacarello I; Caggiano EG; Phan JL; Deorukhkar A; Molkentine JM; Saur D; Maitra A; Taniguchi CM
Gastroenterology; 2022 Jun; 162(7):2018-2031. PubMed ID: 35216965
[TBL] [Abstract][Full Text] [Related]
7. A First-in-Human Phase 1 Study of a Tumor-Directed RNA-Interference Drug against HIF2α in Patients with Advanced Clear Cell Renal Cell Carcinoma.
Brugarolas J; Obara G; Beckermann KE; Rini B; Lam ET; Hamilton J; Schluep T; Yi M; Wong S; Mao ZL; Gamelin E; Tannir NM
Clin Cancer Res; 2024 Apr; ():OF1-OF10. PubMed ID: 38652038
[TBL] [Abstract][Full Text] [Related]
8. Targeting the HIF2-VEGF axis in renal cell carcinoma.
Choueiri TK; Kaelin WG
Nat Med; 2020 Oct; 26(10):1519-1530. PubMed ID: 33020645
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia-Inducible Factor 2-Dependent Pathways Driving Von Hippel-Lindau-Deficient Renal Cancer.
Meléndez-Rodríguez F; Roche O; Sanchez-Prieto R; Aragones J
Front Oncol; 2018; 8():214. PubMed ID: 29938199
[TBL] [Abstract][Full Text] [Related]
10. Enhanceosomes as integrators of hypoxia inducible factor (HIF) and other transcription factors in the hypoxic transcriptional response.
Pawlus MR; Hu CJ
Cell Signal; 2013 Sep; 25(9):1895-903. PubMed ID: 23707522
[TBL] [Abstract][Full Text] [Related]
11. von-Hippel Lindau and Hypoxia-Inducible Factor at the Center of Renal Cell Carcinoma Biology.
Shirole NH; Kaelin WG
Hematol Oncol Clin North Am; 2023 Oct; 37(5):809-825. PubMed ID: 37270382
[TBL] [Abstract][Full Text] [Related]
12. The role of HIF1α in renal cell carcinoma tumorigenesis.
Gudas LJ; Fu L; Minton DR; Mongan NP; Nanus DM
J Mol Med (Berl); 2014 Aug; 92(8):825-36. PubMed ID: 24916472
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
